Genes That Affect Disease Outcome in Patients With Metastatic Colorectal Cancer
This trial is active, not recruiting.
|Treatments||microarray analysis, mutation analysis, polymerase chain reaction, polymorphism analysis, laboratory biomarker analysis, questionnaire administration|
|Sponsor||University of Sheffield|
|Start date||July 2002|
|Trial size||800 participants|
|Trial identifier||NCT00467129, CDR0000540670, EU-20727, SHEFF-SSREC01/271, SHEFF-USMS-SSREC01/271|
RATIONALE: Studying samples of blood and tumor tissue in the laboratory from patients with cancer may help doctors learn more about changes that occur in DNA and help doctors understand how patients respond to treatment.
PURPOSE: This clinical trial is examining genes that affect disease outcome in patients with metastatic colorectal cancer.
Progressive disease-free survival
Male or female participants of any age.
DISEASE CHARACTERISTICS: - Diagnosis of metastatic colorectal cancer - Currently receiving chemotherapy at Weston Park Hospital PATIENT CHARACTERISTICS: - Not Specified PRIOR CONCURRENT THERAPY: - See Disease Characteristics
|Official title||The Role of Genetic Factors in Clinical Outcome for Colorectal Cancer|
|Description||OBJECTIVES: - Collect blood samples for DNA extraction for genetic studies from patients receiving chemotherapy for metastatic colorectal cancer. - Collect detailed clinical, pathological, and chemotherapy data from these patients. - Identify genetic factors that relate to treatment response and outcome in these patients. OUTLINE: Blood samples are collected and relevant genes and regions are amplified by PCR. PCR products are then sequenced or genotyped for known biological markers and single nucleotide polymorphisms. Tumor samples from surplus pathology specimens are analyzed for expression of candidate genes and mutation in the candidate genes. Clinical and family history data is also collected by questionnaire. PROJECTED ACCRUAL: A total of 800 patients will be accrued for this study.|
Call for more information